Claims for Patent: 9,974,790

Summary for Patent: 9,974,790

Title:	Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Abstract:	The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s):	Rodgers; James D. (Landenberg, PA), Shepard; Stacey (Wilmington, DE)
Assignee:	Incyte Corporation (Wilmington, DE) Incyte Holdings Corporation (Wilmington, DE)
Application Number:	15/356,957
Patent Claims:	1. A method of inhibiting JAK1 and/or JAK2 in a patient suffering from an autoimmune skin disease, comprising administering to the patient a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]prop- anenitrile, or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl- ]propanenitrile, or a pharmaceutically acceptable salt thereof. 3. The method of claim 2, wherein the compound or salt is administered as a pharmaceutical composition comprising the compound or the salt and a pharmaceutically acceptable carrier. 4. The method of claim 3, wherein the pharmaceutical composition is suitable for topical administration. 5. The method of claim 3, wherein the pharmaceutical composition is suitable for oral administration. 6. The method of claim 3, wherein about 5 to about 1000 mg of the compound, or pharmaceutically acceptable salt thereof, is administered to the patient. 7. The method of claim 2, further comprising administering to the patient at least one additional therapeutic agent. 8. The method of claim 7, wherein the therapeutic agent is administered to a patient simultaneously or sequentially. 9. The method of claim 7, wherein said therapeutic agent is an immunosuppressant. 10. The method of claim 7, wherein said therapeutic agent is a steroid. 11. The method of claim 7, wherein said therapeutic agent is a corticosteroid. 12. The method of claim 11, wherein said corticosteroid is dexamethasone or prednisone. 13. The method of claim 11, wherein said corticosteroid is dexamethasone. 14. The method of claim 11, wherein said corticosteroid is prednisone.